Show simple item record

dc.contributor.authorCoates, Laura C
dc.contributor.authorConaghan, Philip G
dc.contributor.authorD'Agostino, Maria Antonietta
dc.contributor.authorDe Wit, Maarten
dc.contributor.authorFitzGerald, Oliver
dc.contributor.authorKvien, Tore K
dc.contributor.authorLories, Rik
dc.contributor.authorMease, Philip
dc.contributor.authorNash, Peter
dc.contributor.authorSchett, Georg
dc.contributor.authorSoriano, Enrique R
dc.contributor.authorEmery, Paul
dc.date.accessioned2020-08-06T21:26:51Z
dc.date.available2020-08-06T21:26:51Z
dc.date.issued2018
dc.identifier.issn1462-0324
dc.identifier.doi10.1093/rheumatology/kex344
dc.identifier.urihttp://hdl.handle.net/10072/395968
dc.description.abstractAdvances in treatments and treatment strategies for PsA have led to many patients responding well to management of their disease, and targeting remission as a treatment goal is now a possibility. Treat to target is a strategy aimed at maximizing benefit, irrespective of the type of medication used, by monitoring disease activity and using it to guide therapy. The measurement of response to treatment has been the subject of wide discussions among experts for some time, and many instruments exist. Comparisons of the different measures and their different strengths and weaknesses is ongoing. The impact of modern imaging techniques on monitoring disease progression is also evolving, and advanced techniques using both MRI and US have the potential to improve management of PsA through identification of risk factors for poor prognosis as well as accurate assessment of inflammation and damage, including subclinical disease. Increased understanding of the pathways that drive the pathogenesis of PsA will be key to identifying specific biomarkers for the disease and developing effective treatment strategies. Targets for response, considerations for use of a treat to target strategy in PsA, different imaging techniques and serological aspects of remission are all discussed in this review, and areas for further research are identified.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherOxford University Press
dc.relation.ispartofpagefrom1321
dc.relation.ispartofpageto1331
dc.relation.ispartofissue8
dc.relation.ispartofjournalRheumatology
dc.relation.ispartofvolume57
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1107
dc.subject.fieldofresearchcode1117
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsRheumatology
dc.subject.keywordsPsA
dc.subject.keywordsremission
dc.titleRemission in psoriatic arthritis-where are we now?
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationCoates, LC; Conaghan, PG; D'Agostino, MA; De Wit, M; FitzGerald, O; Kvien, TK; Lories, R; Mease, P; Nash, P; Schett, G; Soriano, ER; Emery, P, Remission in psoriatic arthritis-where are we now?, Rheumatology, 2018, 57 (8), pp. 1321-1331
dc.date.updated2020-07-30T23:00:52Z
dc.description.versionPost-print
gro.rights.copyright© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Rheumatology following peer review. The definitive publisher-authenticated version Remission in psoriatic arthritis—where are we now?, Rheumatology, Volume 57, Issue 8, August 2018 is available online at: 10.1093/rheumatology/kex344
gro.hasfulltextFull Text
gro.griffith.authorNash, Peter


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record